Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference